Corcept Therapeutics Incorporated (NASDAQ:CORT) saw a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 9,483,693 shares, a growth of 27.2% from the November 15th total of 7,454,470 shares. Based on an average daily volume of 1,321,982 shares, the days-to-cover ratio is currently 7.2 days. Approximately 9.4% of the company’s stock are short sold.

Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Piper Jaffray Companies set a $30.00 price objective on Corcept Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Stifel Nicolaus began coverage on Corcept Therapeutics in a research note on Thursday, August 31st. They issued a “buy” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $18.20.

In related news, Director G Leonard Baker, Jr. sold 30,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $17.59, for a total transaction of $527,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $16.72, for a total value of $133,760.00. Following the sale, the insider now owns 8,000 shares of the company’s stock, valued at approximately $133,760. The disclosure for this sale can be found here. 19.20% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Suntrust Banks Inc. lifted its holdings in Corcept Therapeutics by 4.0% during the 2nd quarter. Suntrust Banks Inc. now owns 12,308 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 471 shares in the last quarter. Strs Ohio lifted its holdings in Corcept Therapeutics by 2.0% during the 2nd quarter. Strs Ohio now owns 72,900 shares of the biotechnology company’s stock worth $860,000 after purchasing an additional 1,400 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Corcept Therapeutics by 0.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 347,171 shares of the biotechnology company’s stock valued at $4,097,000 after acquiring an additional 2,360 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Corcept Therapeutics by 52.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 3,390 shares in the last quarter. Finally, American International Group Inc. raised its holdings in shares of Corcept Therapeutics by 8.1% in the 3rd quarter. American International Group Inc. now owns 61,110 shares of the biotechnology company’s stock valued at $1,179,000 after acquiring an additional 4,569 shares in the last quarter. 64.71% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics (CORT) opened at $17.16 on Wednesday. Corcept Therapeutics has a 1 year low of $6.70 and a 1 year high of $20.77. The company has a market capitalization of $1,916.15, a price-to-earnings ratio of 57.90 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). The firm had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The firm’s quarterly revenue was up 96.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.02 EPS. analysts predict that Corcept Therapeutics will post 0.47 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Corcept Therapeutics Incorporated (CORT) Short Interest Update” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/13/corcept-therapeutics-incorporated-cort-short-interest-update.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.